Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.

Chapuis N, Poulain L, Birsen R, Tamburini J, Bouscary D.

Front Oncol. 2019 May 22;9:405. doi: 10.3389/fonc.2019.00405. eCollection 2019. Review.

2.

Response of the Aerodyne Aerosol Mass Spectrometer to Inorganic Sulfates and Organosulfur Compounds: Applications in Field and Laboratory Measurements.

Chen Y, Xu L, Humphry T, Hettiyadura APS, Ovadnevaite J, Huang S, Poulain L, Schroder JC, Campuzano-Jost P, Jimenez JL, Herrmann H, O'Dowd C, Stone EA, Ng NL.

Environ Sci Technol. 2019 May 7;53(9):5176-5186. doi: 10.1021/acs.est.9b00884. Epub 2019 Apr 24.

PMID:
30939000
3.

Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation.

Bonnefond ML, Florent R, Lenoir S, Lambert B, Abeilard E, Giffard F, Louis MH, Elie N, Briand M, Vivien D, Poulain L, Gauduchon P, N'Diaye M.

Oncotarget. 2018 Sep 21;9(74):33896-33911. doi: 10.18632/oncotarget.26084. eCollection 2018 Sep 21.

4.

Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.

Hedir S, De Giorgi M, Fogha J, De Pascale M, Weiswald LB, Brotin E, Marekha B, Denoyelle C, Denis C, Suzanne P, Gautier F, Juin P, Ligat L, Lopez F, Carlier L, Legay R, Bureau R, Rault S, Poulain L, Oliveira Santos JS, Voisin-Chiret AS.

Eur J Med Chem. 2018 Nov 5;159:357-380. doi: 10.1016/j.ejmech.2018.10.003. Epub 2018 Oct 4.

PMID:
30308410
5.

Corrigendum: Collocated observations of cloud condensation nuclei, particle size distributions, and chemical composition.

Schmale J, Henning S, Henzing B, Keskinen H, Sellegri K, Ovadnevaite J, Bougiatioti A, Kalivitis N, Stavroulas I, Jefferson A, Park M, Schlag P, Kristensson A, Iwamoto Y, Pringle K, Reddington C, Aalto P, Äijälä M, Baltensperger U, Bialek J, Birmili W, Bukowiecki N, Ehn M, Fjæraa AM, Fiebig M, Frank G, Fröhlich R, Frumau A, Furuya M, Hammer E, Heikkinen L, Herrmann E, Holzinger R, Hyono H, Kanakidou M, Kiendler-Scharr A, Kinouchi K, Kos G, Kulmala M, Mihalopoulos N, Motos G, Nenes A, O'Dowd C, Paramonov M, Petäjä T, Picard D, Poulain L, Prévôt ASH, Slowik J, Sonntag A, Swietlicki E, Svenningsson B, Tsurumaru H, Wiedensohler A, Wittbom C, Ogren JA, Matsuki A, Yum SS, Myhre CL, Carslaw K, Stratmann F, Gysel M.

Sci Data. 2018 May 8;5:180094. doi: 10.1038/sdata.2018.94.

6.

Flow cytometry for receptor analysis from ex-vivo brain tissue in adult rat.

Benoit A, Guillamin M, Aitken P, Smith PF, Philoxene B, Sola B, Poulain L, Coquerel A, Besnard S.

J Neurosci Methods. 2018 Jul 1;304:11-23. doi: 10.1016/j.jneumeth.2018.04.005. Epub 2018 Apr 13.

PMID:
29660368
7.

Novel insights on new particle formation derived from a pan-european observing system.

Dall'Osto M, Beddows DCS, Asmi A, Poulain L, Hao L, Freney E, Allan JD, Canagaratna M, Crippa M, Bianchi F, de Leeuw G, Eriksson A, Swietlicki E, Hansson HC, Henzing JS, Granier C, Zemankova K, Laj P, Onasch T, Prevot A, Putaud JP, Sellegri K, Vidal M, Virtanen A, Simo R, Worsnop D, O'Dowd C, Kulmala M, Harrison RM.

Sci Rep. 2018 Jan 24;8(1):1482. doi: 10.1038/s41598-017-17343-9.

8.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
9.

Intermittent hypoxia-induced insulin resistance is associated with alterations in white fat distribution.

Poulain L, Mathieu H, Thomas A, Borel AL, Remy C, Levy P, Arnaud C, Dematteis M.

Sci Rep. 2017 Sep 11;7(1):11180. doi: 10.1038/s41598-017-11782-0.

10.

Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.

Meryet-Figuière M, Lecerf C, Varin E, Coll JL, Louis MH, Dutoit S, Giffard F, Blanc-Fournier C, Hedir S, Vigneron N, Brotin E, Pelletier L, Josserand V, Denoyelle C, Poulain L.

Oncol Rep. 2017 Oct;38(4):1949-1958. doi: 10.3892/or.2017.5882. Epub 2017 Aug 4.

11.

Gene Knockout Shows That PML (TRIM19) Does Not Restrict the Early Stages of HIV-1 Infection in Human Cell Lines.

Masroori N, Cherry P, Merindol N, Li JX, Dufour C, Poulain L, Plourde MB, Berthoux L.

mSphere. 2017 Jun 21;2(3). pii: e00233-17. doi: 10.1128/mSphereDirect.00233-17. eCollection 2017 May-Jun.

12.

Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.

Mandilaras V, Vernon M, Meryet-Figuière M, Karakasis K, Lambert B, Poulain L, Oza A, Denoyelle C, Lheureux S.

Expert Opin Biol Ther. 2017 Aug;17(8):927-943. doi: 10.1080/14712598.2017.1340935. Epub 2017 Jun 22. Review.

PMID:
28641048
13.

Collocated observations of cloud condensation nuclei, particle size distributions, and chemical composition.

Schmale J, Henning S, Henzing B, Keskinen H, Sellegri K, Ovadnevaite J, Bougiatioti A, Kalivitis N, Stavroulas I, Jefferson A, Park M, Schlag P, Kristensson A, Iwamoto Y, Pringle K, Reddington C, Aalto P, Äijälä M, Baltensperger U, Bialek J, Birmili W, Bukowiecki N, Ehn M, Fjæraa AM, Fiebig M, Frank G, Fröhlich R, Frumau A, Furuya M, Hammer E, Heikkinen L, Herrmann E, Holzinger R, Hyono H, Kanakidou M, Kiendler-Scharr A, Kinouchi K, Kos G, Kulmala M, Mihalopoulos N, Motos G, Nenes A, O'Dowd C, Paramonov M, Petäjä T, Picard D, Poulain L, Prévôt AS, Slowik J, Sonntag A, Swietlicki E, Svenningsson B, Tsurumaru H, Wiedensohler A, Wittbom C, Ogren JA, Matsuki A, Yum SS, Myhre CL, Carslaw K, Stratmann F, Gysel M.

Sci Data. 2017 Mar 14;4:170003. doi: 10.1038/sdata.2017.3. Erratum in: Sci Data. 2018 May 08;5:180094.

14.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
15.

Latitudinal and Seasonal Distribution of Particulate MSA over the Atlantic using a Validated Quantification Method with HR-ToF-AMS.

Huang S, Poulain L, van Pinxteren D, van Pinxteren M, Wu Z, Herrmann H, Wiedensohler A.

Environ Sci Technol. 2017 Jan 3;51(1):418-426. doi: 10.1021/acs.est.6b03186. Epub 2016 Dec 20.

PMID:
27996238
16.

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.

Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.

Mol Cancer Ther. 2017 Jan;16(1):102-115. doi: 10.1158/1535-7163.MCT-16-0342. Epub 2016 Dec 15.

17.

Chondrogenic commitment of human umbilical cord blood-derived mesenchymal stem cells in collagen matrices for cartilage engineering.

Gómez-Leduc T, Hervieu M, Legendre F, Bouyoucef M, Gruchy N, Poulain L, de Vienne C, Herlicoviez M, Demoor M, Galéra P.

Sci Rep. 2016 Sep 8;6:32786. doi: 10.1038/srep32786.

18.

Regional air quality in Leipzig, Germany: detailed source apportionment of size-resolved aerosol particles and comparison with the year 2000.

van Pinxteren D, Fomba KW, Spindler G, Müller K, Poulain L, Iinuma Y, Löschau G, Hausmann A, Herrmann H.

Faraday Discuss. 2016 Jul 18;189:291-315. doi: 10.1039/c5fd00228a.

PMID:
27112235
19.

Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.

Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C.

Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2.

20.

An overview of long non-coding RNAs in ovarian cancers.

Meryet-Figuière M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, Denoyelle C.

Oncotarget. 2016 Jul 12;7(28):44719-44734. doi: 10.18632/oncotarget.8089. Review.

21.

Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.

Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, Lantieri L, Wolkenstein P, Vidaud M, Pasmant E, Chapuis N, Parfait B.

Oncotarget. 2016 Jun 14;7(24):35753-35767. doi: 10.18632/oncotarget.7099.

22.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J.

Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.

23.

[Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia].

Tamburini J, Poulain L, Bouscary D, Sujobert P.

Med Sci (Paris). 2015 Oct;31(10):836-9. doi: 10.1051/medsci/20153110009. Epub 2015 Oct 19. French. No abstract available.

24.

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17.

25.

Photocatalytic abatement results from a model street canyon.

Gallus M, Ciuraru R, Mothes F, Akylas V, Barmpas F, Beeldens A, Bernard F, Boonen E, Boréave A, Cazaunau M, Charbonnel N, Chen H, Daële V, Dupart Y, Gaimoz C, Grosselin B, Herrmann H, Ifang S, Kurtenbach R, Maille M, Marjanovic I, Michoud V, Mellouki A, Miet K, Moussiopoulos N, Poulain L, Zapf P, George C, Doussin JF, Kleffmann J.

Environ Sci Pollut Res Int. 2015 Nov;22(22):18185-96. doi: 10.1007/s11356-015-4926-4. Epub 2015 Jul 16.

PMID:
26178827
26.

Highly Oxidized Multifunctional Organic Compounds Observed in Tropospheric Particles: A Field and Laboratory Study.

Mutzel A, Poulain L, Berndt T, Iinuma Y, Rodigast M, Böge O, Richters S, Spindler G, Sipilä M, Jokinen T, Kulmala M, Herrmann H.

Environ Sci Technol. 2015 Jul 7;49(13):7754-61. doi: 10.1021/acs.est.5b00885. Epub 2015 Jun 9.

PMID:
26011767
27.

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.

Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J.

Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21.

28.

Toll-like receptor-4 mediated inflammation is involved in the cardiometabolic alterations induced by intermittent hypoxia.

Poulain L, Richard V, Lévy P, Dematteis M, Arnaud C.

Mediators Inflamm. 2015;2015:620258. doi: 10.1155/2015/620258. Epub 2015 Mar 19. Review.

29.

Construction of a photocatalytic de-polluting field site in the Leopold II tunnel in Brussels.

Boonen E, Akylas V, Barmpas F, Boréave A, Bottalico L, Cazaunau M, Chen H, Daële V, De Marco T, Doussin JF, Gaimoz C, Gallus M, George C, Grand N, Grosselin B, Guerrini GL, Herrmann H, Ifang S, Kleffmann J, Kurtenbach R, Maille M, Manganelli G, Mellouki A, Miet K, Mothes F, Moussiopoulos N, Poulain L, Rabe R, Zapf P, Beeldens A.

J Environ Manage. 2015 May 15;155:136-44. doi: 10.1016/j.jenvman.2015.03.001. Epub 2015 Apr 2.

PMID:
25863437
30.

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation.

Bonnefond ML, Lambert B, Giffard F, Abeilard E, Brotin E, Louis MH, Gueye MS, Gauduchon P, Poulain L, N'Diaye M.

Apoptosis. 2015 Apr;20(4):535-50. doi: 10.1007/s10495-015-1095-3.

31.

First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies.

Gloaguen C, Voisin-Chiret AS, Sopkova-de Oliveira Santos J, Fogha J, Gautier F, De Giorgi M, Burzicki G, Perato S, Pétigny-Lechartier C, Simonin-Le Jeune K, Brotin E, Goux D, N'Diaye M, Lambert B, Louis MH, Ligat L, Lopez F, Juin P, Bureau R, Rault S, Poulain L.

J Med Chem. 2015 Feb 26;58(4):1644-68. doi: 10.1021/jm500672y. Epub 2015 Feb 4.

PMID:
25585174
32.

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.

Denoyelle C, Lambert B, Meryet-Figuière M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, Juin P, Poulain L.

Cell Death Dis. 2014 Oct 9;5:e1445. doi: 10.1038/cddis.2014.389.

33.

Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.

Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L.

Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8.

34.

BMP-2, hypoxia, and COL1A1/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes.

Ollitrault D, Legendre F, Drougard C, Briand M, Benateau H, Goux D, Chajra H, Poulain L, Hartmann D, Vivien D, Shridhar V, Baldi A, Mallein-Gerin F, Boumediene K, Demoor M, Galera P.

Tissue Eng Part C Methods. 2015 Feb;21(2):133-47. doi: 10.1089/ten.TEC.2013.0724. Epub 2014 Jul 31.

35.

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.

Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.

Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18.

36.

Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.

Reikvam H, Tamburini J, Skrede S, Holdhus R, Poulain L, Ersvaer E, Hatfield KJ, Bruserud Ø.

Br J Haematol. 2014 Jan;164(2):200-11. doi: 10.1111/bjh.12611. Epub 2013 Oct 23.

PMID:
24383842
37.

(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.

Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N.

Transl Oncol. 2013 Oct 1;6(5):586-95. eCollection 2013.

38.

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells.

Lincet H, Kafara P, Giffard F, Abeilard-Lemoisson E, Duval M, Louis MH, Poulain L, Icard P.

J Ovarian Res. 2013 Oct 8;6(1):72. doi: 10.1186/1757-2215-6-72.

39.

Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.

Tomasina J, Poulain L, Abeilard E, Giffard F, Brotin E, Carduner L, Carreiras F, Gauduchon P, Rault S, Malzert-Fréon A.

Int J Pharm. 2013 Dec 15;458(1):197-207. doi: 10.1016/j.ijpharm.2013.09.025. Epub 2013 Sep 29.

PMID:
24084450
40.

Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis.

Poulain L, Thomas A, Rieusset J, Casteilla L, Levy P, Arnaud C, Dematteis M.

Eur Respir J. 2014 Feb;43(2):513-22. doi: 10.1183/09031936.00019913. Epub 2013 Sep 26.

41.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D.

Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6.

42.

Sensitization of ovarian carcinoma cells to Bcl-xL-targeting strategies through indirect modulation of Mcl-1 activity by MR22388, a molecule of the tripentone family.

Tomasina J, Malzert-Freon A, Giffard F, Brotin E, Louis MH, Abeilard E, Rault S, Gauduchon P, Poulain L.

J Ovarian Res. 2013 Jun 5;6(1):38. doi: 10.1186/1757-2215-6-38.

43.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
44.

Molecular mechanism of hypoxia-induced chondrogenesis and its application in in vivo cartilage tissue engineering.

Duval E, Baugé C, Andriamanalijaona R, Bénateau H, Leclercq S, Dutoit S, Poulain L, Galéra P, Boumédiene K.

Biomaterials. 2012 Sep;33(26):6042-51. doi: 10.1016/j.biomaterials.2012.04.061. Epub 2012 Jun 6.

PMID:
22677190
45.

[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

Ray-Coquard I, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, Joly F.

Bull Cancer. 2012 Apr 1;99(4):479-98. doi: 10.1684/bdc.2012.1558. Review. French.

46.

Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies.

Icard P, Zhang XD, Lemoisson E, Louis MH, Allouche S, Lincet H, Poulain L.

J Bioenerg Biomembr. 2012 Feb;44(1):81-90. doi: 10.1007/s10863-012-9415-6. Epub 2012 Feb 10. Erratum in: J Bioenerg Biomembr. 2012 Dec;44(6):673. Philippe, Icard [corrected to Icard, Philippe]; Xiao-Dong, Zhang [corrected to Zhang, Xiao-Dong]; Edwige, Lemoisson [corrected to Lemoisson, Edwige]; Marie-Hélène, Louis [corrected to Louis, Marie-Hélène]; Stéphane, Allouche [corrected to Allouche, St.

PMID:
22322892
47.

Understanding the central role of citrate in the metabolism of cancer cells.

Icard P, Poulain L, Lincet H.

Biochim Biophys Acta. 2012 Jan;1825(1):111-6. doi: 10.1016/j.bbcan.2011.10.007. Epub 2011 Nov 10. Review.

PMID:
22101401
48.

Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance.

Lincet H, Guével B, Pineau C, Allouche S, Lemoisson E, Poulain L, Gauduchon P.

J Proteomics. 2012 Feb 2;75(4):1157-69. doi: 10.1016/j.jprot.2011.10.030. Epub 2011 Nov 12.

PMID:
22100381
49.

Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice.

Arnaud C, Poulain L, Lévy P, Dematteis M.

Atherosclerosis. 2011 Dec;219(2):425-31. doi: 10.1016/j.atherosclerosis.2011.07.122. Epub 2011 Aug 31.

50.

Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma?

Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E, Lincet H, Poulain L, Icard P.

Anticancer Res. 2011 Mar;31(3):797-805.

PMID:
21498699

Supplemental Content

Loading ...
Support Center